Baird R W Upgrades Medline (NASDAQ:MDLN) to “Strong-Buy”

Medline (NASDAQ:MDLN) was upgraded by research analysts at Baird R W to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. Wall Street Zen raised Medline to a “hold” rating in a report on Saturday. BNP Paribas initiated coverage on shares of Medline in a research report on Monday. They issued a “neutral” rating and a $38.00 target price for the company. Deutsche Bank Aktiengesellschaft started coverage on Medline in a research note on Monday. They set a “hold” rating and a $40.00 price objective on the stock. Wolfe Research began coverage on shares of Medline in a report on Monday. They issued an “outperform” rating and a $47.00 target price on the stock. Finally, JPMorgan Chase & Co. began coverage on Medline in a research report on Monday. They set an “overweight” rating and a $50.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $46.70.

Medline Price Performance

Shares of Medline stock opened at $42.85 on Monday. Medline has a 52-week low of $34.89 and a 52-week high of $45.50.

Insider Buying and Selling

In other Medline news, Director Andrew J. Mills bought 2,586,206 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were purchased at an average price of $29.00 per share, with a total value of $74,999,974.00. Following the completion of the acquisition, the director directly owned 2,586,206 shares of the company’s stock, valued at $74,999,974. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Charles N. Mills purchased 2,579,310 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were acquired at an average cost of $29.00 per share, with a total value of $74,799,990.00. Following the completion of the acquisition, the director directly owned 2,441,379 shares in the company, valued at $70,799,991. The trade was a -1,870.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Many major firms launched coverage with buy/overweight or strong‑buy ratings and targets clustered between $45 and $52, citing durable growth, margin expansion and a prime‑vendor advantage — this broad analyst stamp is the main driver of the rally today. TipRanks: Surge on analyst buy notes
• Positive Sentiment: Truist initiated coverage with a Buy and a $52 target (the highest among recent initiations), highlighting upside of ~20% vs. the current level — a concrete high‑target call that supports upside momentum. The Fly: Truist initiation
• Positive Sentiment: Analysts point to Medline’s scale (Jefferies highlights a ~$25bn supply‑chain footprint), vertical integration and branded‑mix shift as catalysts for margin expansion — fundamental reasons underpin many buy ratings. Yahoo Finance: Jefferies coverage
• Positive Sentiment: Medline’s IPO raised roughly $7 billion and the stock’s strong market debut has drawn Wall Street attention; post‑IPO liquidity and fresh research coverage are amplifying buying interest. NAI500: Market debut coverage
• Neutral Sentiment: Reported short interest figures are effectively zero/immaterial in the published data, so there’s no visible short‑squeeze signal backing the move — the rally appears driven by buy‑side interest and research coverage. (internal data)
• Negative Sentiment: Not all research is bullish: BNP Paribas put a neutral $38 target (implying downside), and Deutsche Bank issued a hold with a $40 target — these lower targets provide resistance for longer‑term upside and could cap gains if investors focus on valuation. Benzinga: Coverage summary
• Negative Sentiment: Wells Fargo’s equal‑weight $42 target and other neutral/hold calls (Rothschild/Rothschild Redburn) highlight mixed views on near‑term valuation — expect greater sensitivity to execution and margin guidance in coming quarters. Zacks: Analyst initiations

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.